GREENBRIER COMPANIES INC (GBX) earnings date, results and what the price requires
NYSE · SEC CIK 0000923120 · SEC filings checked Oct 16, 2026
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| May 31, 2026 | Jul 1, 2026 | $576.5M | $18.9M | $0.60 | Filing |
| Feb 28, 2026 | Apr 7, 2026 | $587.5M | $15.0M | $0.47 | Filing |
| Nov 30, 2025 | Jan 8, 2026 | $706.1M | $36.4M | $1.14 | Filing |
| Aug 31, 2025 | Oct 28, 2025 | $759.5M | $36.8M | $1.21 | Filing |
| May 31, 2025 | Jul 1, 2025 | $842.7M | $60.1M | $1.86 | Filing |
| Feb 28, 2025 | Apr 7, 2025 | $762.1M | $51.9M | $1.56 | Filing |
| Nov 30, 2024 | Jan 8, 2025 | $875.9M | $55.3M | $1.72 | Filing |
| Aug 31, 2024 | Oct 23, 2024 | $1.05B | $61.6M | $1.91 | Filing |
What would GREENBRIER COMPANIES INC have to report for its valuation to change?
At $39.27, with a 9.0% required return and a 18× earnings multiple in 5 years, earnings per share must grow about -0.4% a year, to $3.36. On that path the next quarter needs diluted EPS near $1.21, against $1.21 in the quarter ended Aug 31, 2025.
Compare buying at the last close now with waiting for results: if the report moves the growth the price requires, the entry price you would accept changes with it.
| Result | Original | Yours |
|---|---|---|
| Required EPS growth / year | -0.4% | -0.4% |
| EPS needed in final year | $3.36 | $3.36 |
Changed: nothing yet. Model: EPS × (1+g)^years × final P/E, discounted at the required return, equals today's price. Inputs: SEC diluted EPS and the dated close above.
Prepare for earnings across my investments — $399/month
Keep working models for the companies you follow, compare your expectations with reported results, and review what changes your investment decision. GBX goes in with your buy-or-wait comparison and assumptions preserved.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.